ArriVent BioPharma (AVBP) Stock Analysis: AI Score & Alternative Data
ArriVent BioPharma — alt-data steady across 90 days
Is ArriVent BioPharma a buy right now? The alternative data says hold. This AVBP stock analysis is built on the 25+ alternative data signals AltIndex tracks on ArriVent BioPharma every day — hiring, web traffic, sentiment, social reach — rolled into an AI Score of 50/100: a Hold. The stock trades at $28.46 with a $1B market cap.
No core signal has moved more than 5% in 90 days — steady, but without the momentum that pushes a stock into buy territory.
AVBP’s broader alt-data profile also covers job postings (1 open roles), headcount (87 employees, according to LinkedIn), and web traffic (3K monthly visits). Every signal links to its own page with full history, the AVBP technical analysis covers RSI, moving averages, and support and resistance, and the full table of everything AltIndex tracks on AVBP is just below.
ArriVent BioPharma AI Stock Analysis
ArriVent BioPharma is a biotechnology company that focuses on developing novel therapeutics for unmet clinical needs. The company has significantly advanced its research and development activities, positioning itself prominently in its specialized niche.
Analysis generated September 29, 2026.
Recent ArriVent BioPharma Stock Alerts
|
ArriVent BioPharma | August 25 Price is up by 6.5% in the last 24h. |
|
ArriVent BioPharma | August 13 Price is down by -6.1% in the last 24h. |
|
ArriVent BioPharma | August 4 Price is up by 6.2% in the last 24h. |
ArriVent BioPharma Alternative Data
| Alternative Data | Value | 3m Change | Trend |
|---|---|---|---|
| Webpage Traffic | 3K | N/A | |
| Job Posts | 1 | N/A | |
| LinkedIn Employees | 87 | N/A | |
| Reddit Mentions | 0 | N/A | |
| X Mentions | 1 | N/A | |
| Stocktwits Mentions | 3 | 200.0% | |
| News Mentions | 1 | N/A | |
| Stocktwits Subscribers | 164 | N/A |
About ArriVent BioPharma (AVBP)
ArriVent BioPharma, Inc. (AVBP) is an innovative biopharmaceutical company committed to advancing groundbreaking therapies for critical unmet needs in oncology and autoimmune diseases. Leveraging proprietary technologies and a robust scientific foundation, ArriVent is focused on delivering improved patient outcomes through its promising pipeline. With strategic positioning in high-growth sectors of the biopharma industry, the company represents an attractive investment opportunity for institutional investors seeking to capitalize on transformative healthcare advancements with the potential for significant market impact.
| Price | $28.46 |
| Target Price | $387.74 |
| Volume | 63,420,177 |
| Market Cap | $1B |
| Year Range | $18 – $35 |
| Dividend Yield | 0% |
| PE Ratio | — |
| Analyst Rating | 38% buy |
| Industry | Biotechnology |
Latest ArriVent BioPharma News
View more →
A CCL21 gene-modified dendritic cell vaccine combined with pembrolizumab in advanced non-small cell lung cancer: a phase I trialOctober 3 - Nature.com |
|
Elysian Appoints Insurance Industry Veterans Ian Thompson and Robin LaChapelle to Strategic Advisory BoardSeptember 10 - Financial Post |
|
Deep Isolation Nuclear initiated with bullish view at ThinkEquity, here's whyAugust 17 - Thefly.com |
See ArriVent BioPharma’s complete price and AI Score history
Sign up to unlock 1-year and all-time charts for AVBP, plus 25+ alternative data signals, AI Scores, and real-time alerts.
Get Started for FREEArriVent BioPharma Earnings & Financial Performance
View all earnings →ArriVent BioPharma Insider Trading Activity
View all →| HILLHOUSE INVESTMENT MANAGEMENT, LTD. filed to sell 3,929,117 shares at $0.0. Dec 10 '25 |
ArriVent BioPharma Congress Trading
View all →| Politician | Filing Date | Type | Size |
|---|---|---|---|
| No congress trades on file. | |||
Stocks Similar to ArriVent BioPharma
See all →| Company | Price | Market Cap | AI Score | |
|---|---|---|---|---|
 |
Alpha Tau MedicalDRTS |
$14.89 0.8% | $1B | 46 |
 |
Inhibrx BiosciencesINBX |
$94.56 2.5% | $1B | 47 |
 |
KalVista PharmaKALV |
$27.00 0.0% | $1B | 62 |
 |
OmerosOMER |
$18.90 1.6% | $1B | 50 |
 |
Maze TherapeuticsMAZE |
$26.43 0.0% | $1B | 59 |
Explore ArriVent BioPharma Data
Frequently Asked Questions: ArriVent BioPharma (AVBP)
ArriVent BioPharma has an AltIndex AI Score of 50/100 (Hold). The score reflects mixed alternative data signals. All investments carry risk.
50/100. The AI Score combines 25+ alternative data signals including job postings, employee sentiment, social media, web traffic, and financials. Scores above 60 = buy, 40–59 = hold, below 40 = sell. Updated daily.
Currently, the price of one share of ArriVent BioPharma (AVBP) stock is $28.46 with a market cap of $1B.
As of today, ArriVent BioPharma’s PE (Price to Earnings) ratio is —.
View the latest ArriVent BioPharma insider transactions to see recent buying and selling activity by company executives and directors.
Check the ArriVent BioPharma congress trading page for the latest disclosed trades by U.S. senators and representatives.
AltIndex tracks 25+ signals including job postings, web traffic, employee sentiment, Reddit mentions, Stocktwits activity, insider transactions, congressional trades, Google Trends, app downloads, and more.
The AVBP stock price chart above shows ArriVent BioPharma’s performance over time alongside its AI Score. Investors can identify patterns, trends, and potential support or resistance levels. View the full ArriVent BioPharma technical analysis for RSI, moving averages, and more.
See the stocks similar to ArriVent BioPharma section on this page for companies in the same industry ranked by market cap and AI Score.
